Format

Send to

Choose Destination
J Thorac Oncol. 2009 Apr;4(4):444-7. doi: 10.1097/JTO.0b013e31819d6f91.

MET pathway as a therapeutic target.

Author information

1
Section of Hematology/Oncology, Department of Medicine, University of Chicago Medical Center, Chicago, Illinois 60637, USA. rsalgia@medicine.bsd.uchicago.edu

Abstract

Dysregulation of mesenchymal-epithelial transition factor receptor tyrosine kinase pathway leads to cell proliferation, protection from apoptosis, angiogenesis, invasion, and metastasis. It can be dysregulated through overexpression, constitutive activation, gene amplification, ligand-dependent activation or mutation. New drugs targeting various mesenchymal-epithelial transition factor pathways are being investigated with promising results.

PMID:
19333071
PMCID:
PMC2664527
DOI:
10.1097/JTO.0b013e31819d6f91
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center